Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MMH-MAP for Mild Cognitive Impairment in Early Rehabilitation of Ischemic Stroke
NCT03815292Phase 3Completed
- Sponsor
- Materia Medica Holding
- Start
- Oct 2018
- Primary completion
- Jan 2020
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Mild Cognitive Impairment (MCI) comparing MMH-MAP with Placebo (2 arms). Primary endpoint: Percentage of Patients With Improved Cognitive Function (The Montreal Cognitive Assessment Test Total Score of the Baseline +1 or More) at 24 weeks. Started Oct 2018; status: completed.
02
Drugs
Prospekta
03
Conditions
Mild Cognitive Impairment (MCI)
Beyond the preview
Go deeper on NCT03815292.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03815292.